Europe Tightens Safety Guidance for Veterinary Vaccines Under Revised EMA Rules

New European Medicines Agency guideline strengthens the assessment of risks to veterinarians, farmers, pet owners and others who may handle veterinary vaccines

EUROPE, July 14, 2026: New European guidance on the safety of people who handle veterinary vaccines has come into operation, marking an important regulatory update for the European animal health industry.

The revised European Medicines Agency guideline on user safety for immunological veterinary medicinal products provides a clearer system for assessing and managing risks linked to veterinary vaccines and other products that work through the immune system.

Copy of Guidelines – guideline-user-safety-immunological-veterinary-medicinal-products-revision-1_en

The guideline applies to new marketing authorisation applications and changes to existing approvals in the European Union.

Veterinary vaccine safety is not only about the animal

When a veterinary vaccine is assessed, companies must show that it is safe and effective for its intended animal use. However, veterinary products are also handled by people.

Veterinarians may inject hundreds of animals. Farmers and breeders may take part in vaccination programmes. Pet owners may handle treated animals. Other people may come into contact with unused vaccine or discarded material.

The EMA guideline makes clear that human exposure must be considered before, during and after a veterinary vaccine is used.

Who is covered by the new EMA veterinary vaccine safety guideline?

The EMA uses a broad definition of a vaccine “user”. It can include veterinarians, farmers, breeders, animal owners and people helping to restrain animals during vaccination.

The assessment must also consider people who may come into contact with a product during storage, preparation, administration and disposal.

This is particularly important in large livestock vaccination programmes, where veterinary teams and farm workers may handle vaccines repeatedly.

Accidental self-injection is a key safety concern

One of the most obvious risks when vaccinating animals is accidental self-injection.

The revised guideline says safety assessments should examine foreseeable accidents including accidental self-injection, swallowing a product and inhalation. Companies must examine how exposure could happen and the possible health effects.

Where a meaningful risk is identified, appropriate precautions or warnings may need to appear in the official product information and package leaflet.

In simple terms, the warning on a veterinary vaccine should reflect the actual risk faced by the person using it.

Pregnant women and people with weakened immunity need specific consideration

The revised EMA guidance specifically highlights vulnerable groups. Safety assessments must consider pregnant women and people with weakened immune systems where relevant.

This can be important for certain live vaccines and products containing ingredients that may create specific risks after accidental exposure.

The aim is not to create unnecessary warnings. The EMA’s approach is to identify the actual risk and provide suitable steps to reduce it.

Clearer warnings could become more important on veterinary vaccine labels

An important purpose of the revised guideline is to support appropriate safety information in the Summary of Product Characteristics and package leaflet.

These warnings may explain who should avoid handling a product, how accidental exposure should be managed and what precautions should be taken during use.

For veterinary medicine companies, this places greater importance on a clear and structured assessment of human exposure risks.

New veterinary vaccine technologies are changing regulation

The timing of the revision is significant. Veterinary vaccine development is changing rapidly, with newer vaccine platforms and more advanced immune-based products entering animal health research and development.

The EMA’s Committee for Veterinary Medicinal Products adopted the revised user-safety guideline in January 2026 as part of updates aligning veterinary guidance with EU Regulation 2019/6 and experience gained under existing rules. The wider regulatory framework has applied since January 2022.

What does the revised EMA guideline mean for animal health companies?

For veterinary vaccine developers, user safety can no longer be treated as a small section at the end of a regulatory file.

Companies seeking approval for veterinary immune-based medicines in Europe need to clearly examine who will handle the product, how exposure may occur, what harm could result and how the risk can be reduced.

Importantly, the EMA says the guideline itself does not require companies to generate specific additional data. Instead, it provides a structured approach to assessing available safety information and managing identified risks.

Europe puts greater focus on people handling veterinary vaccines

The revised EMA veterinary vaccine safety guideline sends a simple message. A veterinary vaccine must be assessed not only for the animal receiving it, but also for the people who store, prepare, administer and dispose of the product.

For veterinarians, farmers and animal owners, clearer precautions could improve awareness of accidental exposure risks.

For animal health companies, the change strengthens the need for clear human safety assessments and practical product warnings. As veterinary vaccine technology develops, Europe is updating its safety guidance to keep pace.